English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/31633
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCasillas-Ramírez, Araní-
dc.contributor.authorZaouali, Mohamed A.-
dc.contributor.authorPadrissa-Altés, Susagna-
dc.contributor.authorMosbah, Ismail Ben-
dc.contributor.authorPertosa, Anna-
dc.contributor.authorXaus, Carme-
dc.contributor.authorRodés, Joan-
dc.contributor.authorRoselló-Catafau, Joan-
dc.contributor.authorPeralta, Carmen-
dc.date.accessioned2011-01-28T08:25:16Z-
dc.date.available2011-01-28T08:25:16Z-
dc.date.issued2009-03-12-
dc.identifier.citationEndocrinology 150(7): 3153–3161 (2009)es_ES
dc.identifier.issn0013-7227-
dc.identifier.urihttp://hdl.handle.net/10261/31633-
dc.description.abstractHepatic steatosis is a major risk factor in ischemia-reperfusion (I/R). IGF-binding proteins (IGFBPs) modulate IGF-I action by transporting circulating IGF-I to its sites of action. Epidermal growth factor (EGF) stimulates IGF-I synthesis in vitro. We examined the effect of IGF-I and EGF treatment, separately or in combination, on the vulnerability of steatotic livers to I/R. Our results indicated that I/R impaired IGF-I synthesis only in steatotic livers. Only when a high dose of IGF-I (400 _g/kg) was given to obese animals did they show high circulating IGF-I:IGFBP levels, increased hepatic IGF-I levels, and protection against damage. In lean animals, a dose of 100 _g/kg IGF-I protected nonsteatotic livers. Our results indicated that the combined administration of IGF-I and EGF resulted in hepatic injury parameters in both liver types similar to that obtained by IGF-I and EGF separately. IGF-I increased egf expression in both liver types. The beneficial role of EGFonhepatic I/R injurymay be attributable to p38 inhibition in nonsteatotic livers and to PPAR_ overexpression in steatotic livers. In conclusion, IGF-I and EGF may constitute new pharmacological strategies to reduce the inherent susceptibility of steatotic livers to I/R injury.es_ES
dc.description.sponsorshipThis work was supported by the Ministerio de Educación y Ciencia (Project Grant SAF 2005-00385) (Madrid, Spain), Ministerio de Sanidad y Consumo (Project Grant PIO60021) (Madrid, Spain), and the Generalitat de Catalunya (2005 SGR/00781 Project) (Barcelona, Spain). Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas is funded by the Instituto de Salud Carlos III.-
dc.language.isoenges_ES
dc.publisherEndocrine Societyes_ES
dc.rightsopenAccesses_ES
dc.titleInsulin-like growth factor and epidermal growth factor treatment: new approaches to protecting steatotic livers against ischemia-reperfusion injuryes_ES
dc.typeartículoes_ES
dc.identifier.doihttp://dx.doi.org/10.1210/en.2008-1458-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1210/en.2008-1458-
dc.identifier.e-issn1945-7170-
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
Insulin-like growth factor.pdf1,45 MBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.